12:00 AM
 | 
Jun 25, 2001
 |  BioCentury  |  Tools & Techniques

Technology Focus

Amylin Inc.'s first generation diabetes compound, Symlin pramlintide, always has been hard for the outside world to understand, because the results of its clinical trials have been complex. The case for the company's next compound in line, AC2993, appears to be much more straightforward.

Over the weekend, AMLN was to release Phase II data on AC2993, showing efficacy on multiple end points related to reductions in glucose. AC2993 (synthetic exendin-4) is a 39-amino acid peptide that exhibits several of the anti-diabetic actions of the hormone glucagon-like peptide-1 (GLP-1). The Phase II trial studied 109 patients with Type II diabetes who were inadequately controlled with oral agents (sulfonylureas or metformin alone or in combination).

"This is a patient population failing the most commonly prescribed oral agents, and more than 50% of them were on both," said Alain Baron, vice president of research at AMLN (San Diego, Calif.). These patients are heading toward needing insulin shots."

Thus the company is positioning AC2993 at the junction where patients are failing their oral drugs and the choice is adding a third or fourth oral agent or going to insulin. "Ours is...

Read the full 937 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >